Evidence map›Paper›PMID 21324728›Full record

ArticleOral oncology2011

Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma.

Chunbo Shao, Weiliang Bai, Jacqueline C Junn, Mamoru Uemura, Patrick T Hennessey, David Zaboli, David Sidransky, Joseph A Califano, Patrick K Ha

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2014
    Article
  9. Review
  10. Article
  11. Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Chunbo ShaoDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Weiliang Bai
Jacqueline C Junn
Mamoru Uemura
Patrick T Hennessey
David Zaboli
David Sidransky
Joseph A Califano
Patrick K Ha
Johns Hopkins University · USGreater Baltimore Medical Center · USChina Medical University · CNNew York Medical College · US

Funding

The role of promoter hypermethylation in adenoid cystic carcinomaK08DE018463 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI HA, PATRICK KYONGMIN · 2007 to 2011
$674k
NIDCR NIH HHS K08 DE018463
6 · The paper itself

Abstract

The transcription factor MYB was recently proposed to be a promising oncogene candidate in salivary gland adenoid cystic carcinoma (ACC). However, the up-regulation of MYB in ACC could not be explained solely by deletion of its 3' end. It is widely accepted that the promoter methylation status can regulate the transcription of genes, especially in human cancers. Therefore, it is important to know whether MYB promoter demethylation could explain the over-expression of MYB in ACC. By using the Methprimer program, we identified nine CpG islands in the promoter of MYB. All of these CpG islands were located within the -864 to +2082 nt region relative to the transcription start site of MYB. We then used bisulfite genomic sequencing to evaluate the methylation levels of the CpG islands of MYB in 18 primary ACC tumors, 13 normal salivary gland tissues and nine cancer cell lines. Using cell lines, we also determined the relative MYB expression levels and correlated these with the methylation levels. With bisulfite genomic sequencing, we found no detectable methylation in the CpG islands of MYB in either ACC or normal salivary gland tissues. There was a variable degree of MYB expression in the cell lines tested, but none of these cell lines demonstrated promoter methylation. Promoter hypomethylation does not appear to explain the differential expression of MYB in ACC. An alternative mechanism needs to be proposed for the transcriptional control of MYB in ACC.

Indexed as

DNA MethylationAdultAgedAged, 80 and overCarcinoma, Adenoid CysticCell Line, TumorCpG IslandsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPromoter Regions, GeneticSalivary Gland NeoplasmsTranscription FactorsUp-RegulationTranscription Factors

Identifiers

PMID21324728
PMCPMC3065551
OpenAlexW2078164756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.